Prediction of glycaemic control and quality of life in people with type 2 diabetes using glucose-lowering drugs with machine learning-The Maastricht study.

Journal: Diabetes, obesity & metabolism
Published Date: Jul 17, 2025

Abstract

BACKGROUND: Despite the heterogeneity of type 2 diabetes (T2D), all patients are treated according to the same guideline. Some people have more difficulty reaching treatment goals (adequate glycaemic control) and maintaining quality of life (QoL). Therefore, a prediction model identifying who is unlikely to reach these goals within the next year would be useful to allow specific attention to these people.

Authors

  • Nikki C C Werkman
    Department of Clinical Pharmacy, Cardiovascular Research Institute Maastricht (CARIM), Maastricht University, Maastricht, The Netherlands.
  • Johannes T H Nielen
    Department of Clinical Pharmacy, Cardiovascular Research Institute Maastricht (CARIM), Maastricht University, Maastricht, The Netherlands.
  • José Tapia-Galisteo
    Bioengineering and Telemedicine Group, Centro de Tecnología Biomédica, ETSI de Telecomunicación, Universidad Politécnica de Madrid, Madrid, Spain.
  • Francisco J Somolinos-Simón
    Bioengineering and Telemedicine Group, Centro de Tecnología Biomédica, ETSI de Telecomunicación, Universidad Politécnica de Madrid, Madrid, Spain.
  • Maria Elena Hernando
    2 Bioengineering and Telemedicine Centre, Universidad Politécnica de Madrid, Spain.
  • Junfeng Wang
    Department of Colorectal Oncology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin's Clinical Research Center for Cancer, Tianjin Key Laboratory of Digestive Cancer, Tianjin, China.
  • Li Jiu
    Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands.
  • Wim G Goettsch
    Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands.
  • Hans Bosma
    Department of Social Medicine, Maastricht University, Maastricht, Netherlands.
  • Miranda T Schram
    CARIM School for Cardiovascular Diseases, Maastricht University, Maastricht, The Netherlands.
  • Marleen M J van Greevenbroek
    Department of Clinical Pharmacy, Cardiovascular Research Institute Maastricht (CARIM), Maastricht University, Maastricht, The Netherlands.
  • Anke Wesselius
    Department of Complex Genetics and Epidemiology, NUTRIM School for Nutrition and Translational Research in Metabolism, Maastricht University, Maastricht, The Netherlands.
  • Coen D A Stehouwer
    CARIM School for Cardiovascular Diseases, Maastricht University, Maastricht, The Netherlands.
  • Johanna H M Driessen
    Department of Clinical Pharmacy, Cardiovascular Research Institute Maastricht (CARIM), Maastricht University, Maastricht, The Netherlands.
  • Gema García-Sáez
    2 Bioengineering and Telemedicine Centre, Universidad Politécnica de Madrid, Spain.

Keywords

No keywords available for this article.

External Resources

Popular Topics
Recent Journals